Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) EBITDA (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed EBITDA for 11 consecutive years, with -$95.7 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 27.24% to -$95.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$412.3 million through Dec 2025, up 20.46% year-over-year, with the annual reading at -$412.3 million for FY2025, 20.46% up from the prior year.
  • EBITDA for Q4 2025 was -$95.7 million at Intellia Therapeutics, up from -$101.0 million in the prior quarter.
  • The five-year high for EBITDA was -$46.2 million in Q1 2021, with the low at -$152.3 million in Q1 2022.
  • Average EBITDA over 5 years is -$107.8 million, with a median of -$109.9 million recorded in 2022.
  • The sharpest move saw EBITDA crashed 229.53% in 2022, then surged 35.43% in 2023.
  • Over 5 years, EBITDA stood at -$83.7 million in 2021, then plummeted by 33.22% to -$111.5 million in 2022, then fell by 17.35% to -$130.8 million in 2023, then decreased by 0.57% to -$131.6 million in 2024, then increased by 27.24% to -$95.7 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$95.7 million, -$101.0 million, and -$101.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.